S3V Launches Domestic Transcatheter Aortic Valve Replacement System with AM Naik Backing

S3V Vascular Technologies Unveils Indigenous Balloon-Expandable TAVR System

Overview

On Thursday, S3V Vascular Technologies, backed by AM Naik, former chairman of L&T, and stock market investors Utpal Sheth and Madhu Kela, announced the launch of its first indigenous Balloon-Expandable Transcatheter Aortic Valve Replacement (TAVR) system. This marks a significant milestone in reducing India's dependence on expensive imported heart-valve devices and widening access to TAVR procedures.

Market Context

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

TAVR, a minimally invasive alternative to open-heart surgery for severe aortic stenosis, has become the global standard for elderly and high-risk patients. However, in India, adoption has remained severely limited due to high device prices and limited reimbursement. Imported TAVR valves currently cost between Rs. 13 lakh to Rs. 23 lakh, leaving procedures accessible to only a fraction of those who need them. Industry estimates suggest that India performs around 4,000 TAVR procedures annually, while the clinical need is closer to 50,000.

Product and Timeline

S3V said its domestically engineered valve aims to significantly bring down costs, creating a more equitable market. The device will undergo preclinical testing to validate performance and safety before progressing to human trials. Subject to regulatory approvals, S3V expects commercial rollout within 12 to 18 months.

Strategic Alignment

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The initiative aligns with national priorities under Atmanirbhar Bharat and Make in India, both of which encourage non-import-dependent innovation in high-technology medical devices. S3V has been investing in structural heart technologies through close collaboration with clinicians and academic partners, with the TAVR programme part of a broader effort to position India as a global hub for high-end cardiovascular innovation.